The active agent in the nasal spray, 2-bromopalmitate, carries a high risk of interfering with a number of processes, making ...

Cassava Sciences' troubled development of Alzheimer's disease candidate simufilam looks like it may have finally reached the ...

Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate ...

While food and lifestyle changes can't completely reverse the effects of Alzheimer's disease, your plate could go a long way ...

Alector’s AbbVie-partnered Alzheimer's asset has failed to slow disease progression in a phase 2 study, the latest in a ...

Alector Therapeutics, working with AbbVie, was testing whether modulating immune cells in brain would slow Alzheimer's ...

Dear Quentin,  I have two sisters who have developed Alzheimer’s disease. My younger sister is actually more severely ...

Alzheimer's disease—the most common form of dementia—is a progressive neurological disorder that causes brain cells to ...

To determine the diagnostic accuracy of the results of CSF tests compared to the gold standard PET imaging, the Munich researchers evaluated the data of over 400 patients with suspected Alzheimer's ...

Cassava Sciences Inc.’s stock crated 85% in premarket trade Monday, after the clinical-stage biotech said a trial of a treatment for mild-to-moderate Alzheimer’s disease failed to meet its main goals.

Nov. 21—John Haldi had early-stage Alzheimer's disease when he began a local Aduhelm drug study in June 2020. For three years ...

A future treatment for Alzheimer disease may involve a nasal spray. Researchers at Università Cattolica and Fondazione Policlinico Universitario A. Gemelli IRCCS have discovered that by inhibiting the ...